Download PDF
Semin Neurol
DOI: 10.1055/s-0044-1791519
Review Article

Hereditary Transthyretin Amyloidosis Polyneuropathy

Taha Qarni
1   Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania
,
Orly Moshe-Lilie
2   Department of Neurology, Boston University, Boston, Massachusetts
,
Michelle C. Kaku
3   Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York
,
Chafic Karam
1   Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

In the last decade, we have witnessed dramatic improvements in the diagnosis, workup, management, and monitoring of patients with hereditary transthyretin amyloidosis (ATTRv). Updated imaging techniques (e.g., 99mTc-PYP scan) are increasingly being used in place of tissue biopsies for confirmation of disease. Novel treatments now include antisense oligonucleotide and RNA interference drugs, whereas new applications such as CRISPR and amyloid antibodies are being studied for potential use in the future. These treatments have dramatically improved quality of life and increased survival in patients with ATTRv. Despite these breakthroughs, many challenges remain. Some of these challenges include early recognition and diagnosis of ATTRv, monitoring and initiation of treatment in asymptomatic or paucisymptomatic carriers, adequate treatment in people with mixed phenotype (i.e., cardiac and neurological), and the emergence of new phenotypes in people living longer with the disease (i.e., central nervous system and ocular complications). Research in those areas of deficit is ongoing, and in the future, we may have preventive therapies, better biomarkers, more efficient therapies for organs that we cannot currently target, and enhanced diagnostic techniques with the help of novel imaging techniques and artificial intelligence. In this review, we will summarize the current knowledge about polyneuropathy related to ATTRv and its management, discuss methods to improve early diagnosis and monitoring, and discuss emerging trends.

Keywords

ATTRv amyloidosis - familial amyloid polyneuropathy - cardiac amyloidosis - hereditary transthyretin amyloidosis


Publication History

Article published online:
15 October 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Maurer MS, Schwartz JH, Gundapaneni B. et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379 (11) 1007-1016
    CrossrefPubMedGoogle Scholar
  • 2 Kanda Y, Goodman DS, Canfield RE, Morgan FJ. The amino acid sequence of human plasma prealbumin. J Biol Chem 1974; 249 (21) 6796-6805
    CrossrefPubMedGoogle Scholar
  • 3 Kelly JW, Colon W, Lai Z. et al. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 1997; 50: 161-181
    CrossrefPubMedGoogle Scholar
  • 4 Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev 2022; 27 (03) 785-793
    CrossrefPubMedGoogle Scholar
  • 5 Karam C, Dimitrova D, Christ M, Heitner SB. Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis. Neurol Clin Pract 2019; 9 (04) 309-313
    CrossrefPubMedGoogle Scholar
  • 6 Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75 (03) 408-427
    PubMedGoogle Scholar
  • 7 Benson MD, Waddington-Cruz M, Berk JL. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379 (01) 22-31
    CrossrefPubMedGoogle Scholar
  • 8 Adams D, Gonzalez-Duarte A, O'Riordan WD. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379 (01) 11-21
    CrossrefPubMedGoogle Scholar
  • 9 Berk JL, Suhr OB, Obici L. et al; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310 (24) 2658-2667
    CrossrefPubMedGoogle Scholar
  • 10 Coelho T, Maia LF, Martins da Silva A. et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79 (08) 785-792
    CrossrefPubMedGoogle Scholar
  • 11 Schmidt HH, Waddington-Cruz M, Botteman MF. et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 2018; 57 (05) 829-837
    CrossrefPubMedGoogle Scholar
  • 12 Schmidt H, Cruz MW, Botteman MF. et al. Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review. Amyloid 2017; 24 (sup1): 111-112
    CrossrefPubMedGoogle Scholar
  • 13 Carroll A, Dyck PJ, de Carvalho M. et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry 2022; 93 (06) 668-678
    CrossrefPubMedGoogle Scholar
  • 14 Conceição I. Clinical features of TTR-FAP in Portugal. Amyloid 2012; 19 (Suppl. 01) 71-72
    CrossrefPubMedGoogle Scholar
  • 15 Planté-Bordeneuve V, Carayol J, Ferreira A. et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003; 40 (11) e120
    CrossrefPubMedGoogle Scholar
  • 16 Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15 (03) 181-186
    CrossrefPubMedGoogle Scholar
  • 17 Jacobson DR, Pastore RD, Yaghoubian R. et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997; 336 (07) 466-473
    CrossrefPubMedGoogle Scholar
  • 18 Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR epidemiology, genetics, and prognostic factors. Methodist DeBakey Cardiovasc J 2022; 18 (02) 17-26
    CrossrefPubMedGoogle Scholar
  • 19 Madhani A, Sabogal N, Massillon D. et al. Clinical penetrance of the transthyretin V122I variant in older Black patients with heart failure: the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. J Am Heart Assoc 2023; 12 (15) e028973
    CrossrefPubMedGoogle Scholar
  • 20 Saporta MAC, Zaros C, Cruz MW. et al. Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families. Eur J Neurol 2009; 16 (03) 337-341
    CrossrefPubMedGoogle Scholar
  • 21 Poli L, Labella B, Cotti Piccinelli S. et al. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol 2023; 14: 1242815
    CrossrefPubMedGoogle Scholar
  • 22 Lin X, Yarlas A, Vera-Llonch M. et al. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis. BMC Neurol 2021; 21 (01) 70
    CrossrefPubMedGoogle Scholar
  • 23 Wang S, Peng W, Pang M. et al. Clinical profile and prognosis of hereditary transthyretin amyloid cardiomyopathy: a single-center study in South China. Front Cardiovasc Med 2022; 9: 900313
    CrossrefPubMedGoogle Scholar
  • 24 Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A. et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail 2022; 24 (09) 1677-1696
    CrossrefPubMedGoogle Scholar
  • 25 Gonzalez-Duarte A, Valdés-Ferrer SI, Cantú-Brito C. Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review. Clin Auton Res 2019; 29 (Suppl. 01) 1-9
    CrossrefPubMedGoogle Scholar
  • 26 Blake CCF, Geisow MJ, Swan IDA, Rerat C, Rerat B. Structure of human plasma prealbumin at 2-5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol 1974; 88 (01) 1-12
    CrossrefPubMedGoogle Scholar
  • 27 Saraiva MJM. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat 2001; 17 (06) 493-503
    CrossrefPubMedGoogle Scholar
  • 28 Dickson PW, Aldred AR, Marley PD, Tu GF, Howlett GJ, Schreiber G. High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain. Biochem Biophys Res Commun 1985; 127 (03) 890-895
    CrossrefPubMedGoogle Scholar
  • 29 Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem 1985; 260 (21) 11793-11798
    CrossrefPubMedGoogle Scholar
  • 30 Guimaraes A, Viana Pinherio A, Leite I. Sural nerve biopsy in familial amyloidotic polyneuropathy: a morphological and morphometric polyneuropathy. In: Natvig JB, Forre O, Husby G. et al., eds. Amyloid and Amyloidosis. Kluwer Academic Publishers; 1990: 493-498
    Google Scholar
  • 31 Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 2012; 7 (08) 1337-1346
    CrossrefPubMedGoogle Scholar
  • 32 Lobato L, Beirão I, Guimarães SM. et al. Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits. Am J Kidney Dis 1998; 31 (06) 940-946
    CrossrefPubMedGoogle Scholar
  • 33 Wixner J, Törnblom H, Karling P, Anan I, Lindberg G. Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis. Neurogastroenterol Motil 2018; 30 (09) e13354
    CrossrefPubMedGoogle Scholar
  • 34 Ikeda SI, Makishita H, Oguchi K, Yanagisawa N, Nagata T. Gastrointestinal amyloid deposition in familial amyloid polyneuropathy. Neurology 1982; 32 (12) 1364-1368
    CrossrefPubMedGoogle Scholar
  • 35 Obayashi K, Olsson M, Anan I. et al. Impact of serotonin transporter and catechol-O-methyl transferase genes polymorphism on gastrointestinal dysfunction in Swedish and Japanese familial amyloidotic polyneuropathy patients. Clin Chim Acta 2008; 398 (1–2): 10-14
    CrossrefPubMedGoogle Scholar
  • 36 El-Salhy M, Suhr O. Endocrine cells in rectal biopsy specimens from patients with familial amyloidotic polyneuropathy. Scand J Gastroenterol 1996; 31 (01) 68-73
    CrossrefPubMedGoogle Scholar
  • 37 Anan I, El-Salhy M, Ando Y. et al. Colonic endocrine cells in patients with familial amyloidotic polyneuropathy. J Intern Med 1999; 245 (05) 469-473
    CrossrefPubMedGoogle Scholar
  • 38 Hou X, Parkington HC, Coleman HA. et al. Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J Neurochem 2007; 100 (02) 446-457
    CrossrefPubMedGoogle Scholar
  • 39 Said G. Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 2003; 10 (Suppl. 01) 7-12
    CrossrefPubMedGoogle Scholar
  • 40 Koike H, Ikeda S, Takahashi M. et al. Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology 2016; 87 (21) 2220-2229
    CrossrefPubMedGoogle Scholar
  • 41 Kollmer J, Hund E, Hornung B. et al. In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain 2015; 138 (Pt 3): 549-562
    CrossrefPubMedGoogle Scholar
  • 42 Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 2008; 216 (02) 253-261
    CrossrefPubMedGoogle Scholar
  • 43 Koike H, Ando Y, Ueda M. et al. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci 2009; 287 (1-2): 178-184
    CrossrefPubMedGoogle Scholar
  • 44 Koike H, Misu K, Sugiura M. et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 2004; 63 (01) 129-138
    CrossrefPubMedGoogle Scholar
  • 45 Sobue G, Nakao N, Murakami K. et al. Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system. Brain 1990; 113 (Pt 4): 903-919
    CrossrefPubMedGoogle Scholar
  • 46 Wakita Y, Sato T, Chosa K. et al. Characterization of non-amyloidogenic G101S transthyretin. Biol Pharm Bull 2018; 41 (04) 628-636
    CrossrefPubMedGoogle Scholar
  • 47 Miller M, Pal A, Albusairi W. et al. Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis. J Med Chem 2018; 61 (17) 7862-7876
    CrossrefPubMedGoogle Scholar
  • 48 Sant'Anna R, Almeida MR, Varejāo N. et al. Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Sci Rep 2017; 7: 44709
    CrossrefPubMedGoogle Scholar
  • 49 Lim A, Prokaeva T, Connor LH, Falk RH, Skinner M, Costello CE. Identification of a novel transthyretin Thr59Lys/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis. Amyloid 2002; 9 (02) 134-140
    CrossrefPubMedGoogle Scholar
  • 50 Hornstrup LS, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy. Arterioscler Thromb Vasc Biol 2013; 33 (06) 1441-1447
    CrossrefPubMedGoogle Scholar
  • 51 Dispenzieri A, Coelho T, Conceição I. et al; THAOS investigators. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet J Rare Dis 2022; 17 (01) 236
    CrossrefPubMedGoogle Scholar
  • 52 Kaku M, Berk JL. Neuropathy associated with systemic amyloidosis. Semin Neurol 2019; 39 (05) 578-588
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Gertz MA, Benson MD, Dyck PJ. et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66 (21) 2451-2466
    CrossrefPubMedGoogle Scholar
  • 54 Koike H, Misu K, Ikeda S. et al; Study Group for Hereditary Neuropathy in Japan. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 2002; 59 (11) 1771-1776
    CrossrefPubMedGoogle Scholar
  • 55 Pinto MV, Pinto LF, Dias M. et al. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: characterization of Brazilian subjects from the THAOS registry. J Neurol Sci 2019; 403: 1-6
    CrossrefPubMedGoogle Scholar
  • 56 Sattianayagam PT, Hahn AF, Whelan CJ. et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012; 33 (09) 1120-1127
    CrossrefPubMedGoogle Scholar
  • 57 Kaku MC, Bhadola S, Berk JL, Sanchorawala V, Connors LH, Lau KHV. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid 2022; 29 (03) 184-189
    CrossrefPubMedGoogle Scholar
  • 58 da Silva-Batista JA, Marques Jr W, Oliveira MTJS. et al. Presence of val30Met and val122ile mutations in a patient with hereditary amyloidosis. J Hum Genet 2020; 65 (08) 711-713
    CrossrefPubMedGoogle Scholar
  • 59 Prokaeva T, Klimtchuk ES, Feschenko P. et al. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis. Amyloid 2023; 30 (02) 141-152
    CrossrefPubMedGoogle Scholar
  • 60 Taipa R, Sousa L, Pinto M. et al. Neuropathology of central nervous system involvement in TTR amyloidosis. Acta Neuropathol 2023; 145 (01) 113-126
    CrossrefPubMedGoogle Scholar
  • 61 Maia LF, Magalhães R, Freitas J. et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry 2015; 86 (02) 159-167
    CrossrefPubMedGoogle Scholar
  • 62 Karam C, Dimitrova D, Heitner SB. Misdiagnosis of hATTR amyloidosis: a single US site experience. Amyloid 2020; 27 (01) 69-70
    CrossrefPubMedGoogle Scholar
  • 63 Vera-Llonch M, Reddy SR, Chang E, Tarbox MH, Pollock M. The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis. Orphanet J Rare Dis 2021; 16 (01) 25
    CrossrefPubMedGoogle Scholar
  • 64 Benson MD, Dasgupta NR, Rao R. Diagnosis and screening of patients with hereditary transthyretin amyloidosis (Hattr): current strategies and guidelines. Ther Clin Risk Manag 2020; 16: 749-758
    CrossrefPubMedGoogle Scholar
  • 65 Karam C, Mauermann ML, Gonzalez-Duarte A. et al. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts. Muscle Nerve 2024; 69 (03) 273-287
    CrossrefPubMedGoogle Scholar
  • 66 Adams D, Tournev IL, Taylor MS. et al; HELIOS-A Collaborators. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 2023; 30 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 67 Coelho T, Marques Jr W, Dasgupta NR. et al; NEURO-TTRansform Investigators. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 2023; 330 (15) 1448-1458
    CrossrefPubMedGoogle Scholar
  • 68 Ticau S, Aldinc E, Polydefkis M. et al; Patisiran Global OLE Collaborators. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid 2024; 31 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 69 Carroll AS, Razvi Y, O'Donnell L. et al. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice. Amyloid 2024; 31 (02) 95-104
    CrossrefPubMedGoogle Scholar
  • 70 Vogt B, Chahin N, Wiszniewski W, Ragole T, Karam C. Screening for genetic mutations in patients with neuropathy without definite etiology is useful. J Neurol 2020; 267 (09) 2648-2654
    CrossrefPubMedGoogle Scholar
  • 71 Sekijima Y, Nakamura K. Hereditary transthyretin amyloidosis. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A. eds. GeneReviews. Seattle (WA): University of Washington, Seattle; 1993
    Google Scholar
  • 72 Reddi HV, Jenkins S, Theis J. et al. Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life. J Mol Diagn 2014; 16 (01) 68-74
    CrossrefPubMedGoogle Scholar
  • 73 Obici L, Kuks JB, Buades J. et al; European Network for TTR-FAP (ATTReuNET). Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 2016; 29 (Suppl. 01) S27-S35
    CrossrefPubMedGoogle Scholar
  • 74 Lozeron P, Mariani LL, Dodet P. et al. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 2018; 91 (02) e143-e152
    CrossrefPubMedGoogle Scholar
  • 75 Salvalaggio A, Coraci D, Cacciavillani M. et al. Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. J Neurol 2021; 268 (01) 189-198
    CrossrefPubMedGoogle Scholar
  • 76 Hodel J, Benadjaoud S, Benadjaoud MA, Lefaucheur JP, Planté-Bordeneuve V. 3-T MR neurography of lumbo-sacral plexus in hereditary transthyretin-related amyloidosis with polyneuropathy. Eur Radiol 2022; 32 (11) 7865-7871
    CrossrefPubMedGoogle Scholar
  • 77 Gasparotti R, Salvalaggio A, Corbo D. et al. Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy. J Neurol 2023; 270 (10) 4827-4840
    CrossrefPubMedGoogle Scholar
  • 78 Ebenezer GJ, Liu Y, Judge DP. et al. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol 2017; 82 (01) 44-56
    CrossrefPubMedGoogle Scholar
  • 79 Luigetti M, Romozzi M, Bisogni G. et al. hATTR pathology: nerve biopsy results from Italian referral centers. Brain Sci 2020; 10 (11) 780
    CrossrefPubMedGoogle Scholar
  • 80 Samões R, Taipa R, Valdrez K. et al. Amyloid detection in the transverse carpal ligament of patients with hereditary ATTR V30M amyloidosis and carpal tunnel syndrome. Amyloid 2017; 24 (02) 73-77
    CrossrefPubMedGoogle Scholar
  • 81 de Paula Eduardo F, de Mello Bezinelli L, de Carvalho DLC. et al. Minor salivary gland biopsy for the diagnosis of familial amyloid polyneuropathy. Neurol Sci 2017; 38 (02) 311-318
    CrossrefPubMedGoogle Scholar
  • 82 Quarta CC, Gonzalez-Lopez E, Gilbertson JA. et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017; 38 (24) 1905-1908
    CrossrefPubMedGoogle Scholar
  • 83 Paulsson Rokke H, Sadat Gousheh N, Westermark P. et al. Abdominal fat pad biopsies exhibit good diagnostic accuracy in patients with suspected transthyretin amyloidosis. Orphanet J Rare Dis 2020; 15 (01) 278
    CrossrefPubMedGoogle Scholar
  • 84 Gillmore JD, Maurer MS, Falk RH. et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133 (24) 2404-2412
    CrossrefPubMedGoogle Scholar
  • 85 Chatzantonis G, Bietenbeck M, Elsanhoury A. et al. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol 2021; 110 (04) 555-568
    CrossrefPubMedGoogle Scholar
  • 86 Gilbertson JA, Theis JD, Vrana JA. et al. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J Clin Pathol 2015; 68 (04) 314-317
    CrossrefPubMedGoogle Scholar
  • 87 Klein CJ, Vrana JA, Theis JD. et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011; 68 (02) 195-199
    CrossrefPubMedGoogle Scholar
  • 88 Castano A, Haq M, Narotsky DL. et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016; 1 (08) 880-889
    CrossrefPubMedGoogle Scholar
  • 89 Dyck PJB, González-Duarte A, Obici L. et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS + 7. J Neurol Sci 2019; 405: 116424
    CrossrefPubMedGoogle Scholar
  • 90 Adams D, Samuel D, Goulon-Goeau C. et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123 (Pt 7): 1495-1504
    CrossrefPubMedGoogle Scholar
  • 91 Yamashita T, Ando Y, Okamoto S. et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012; 78 (09) 637-643
    CrossrefPubMedGoogle Scholar
  • 92 Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 2015; 21 (03) 282-292
    CrossrefPubMedGoogle Scholar
  • 93 Maurer MS, Kale P, Fontana M. et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 2023; 389 (17) 1553-1565
    CrossrefPubMedGoogle Scholar
  • 94 Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid 2020; 27 (01) 52-58
    CrossrefPubMedGoogle Scholar
  • 95 Coelho T, Adams D, Conceição I. et al. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis 2020; 15 (01) 179
    CrossrefPubMedGoogle Scholar
  • 96 Qarni TN, Jones FJS, Drachman B. et al. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study. Orphanet J Rare Dis 2024; May 8; 19 (01) 191
    CrossrefPubMedGoogle Scholar
  • 97 Gillmore JD, Judge DP, Cappelli F. et al; ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024; 390 (02) 132-142
    CrossrefPubMedGoogle Scholar
  • 98 Gamez J, Salvadó M, Reig N. et al. Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Amyloid 2019; 26 (02) 74-84
    CrossrefPubMedGoogle Scholar
  • 99 Hosoi A, Su Y, Torikai M. et al. Novel antibody for the treatment of transthyretin amyloidosis. J Biol Chem 2016; 291 (48) 25096-25105
    CrossrefPubMedGoogle Scholar